Rao Veena S, Christenbury Joseph, Lee Paul, Allingham Rand, Herndon Leon, Challa Pratap
*Duke Eye Center, Duke University Medical Center, Durham, NC †Kellogg Eye Center, University of Michigan, Ann Arbor, MI.
J Glaucoma. 2017 Feb;26(2):101-106. doi: 10.1097/IJG.0000000000000531.
To evaluate efficacy and safety of a novel technique, simultaneous implantation of Ahmed and Baerveldt shunts, for improved control of intraocular pressure (IOP) in advanced glaucoma with visual field defects threatening central fixation.
Retrospective case series; all patients receiving simultaneous Ahmed and Baerveldt implantation at a single institution between October 2004 and October 2009 were included. Records were reviewed preoperatively and at postoperative day 1, week 1, month 1, month 3, month 6, year 1, and yearly until year 5. Outcome measures included IOP, best-corrected visual acuity, visual field mean deviation, cup to disc ratio, number of glaucoma medications, and complications.
Fifty-nine eyes were identified; mean (±SD) follow-up was 26±23 months. Primary open-angle glaucoma was most common (n=37, 63%). Forty-six eyes (78%) had prior incisional surgery. Mean preoperative IOP was 25.5±9.8 mm Hg. IOP was reduced 50% day 1 (P<0.001, mean 12.7±7.0 mm Hg), which persisted throughout follow-up. At year 1, cup to disc ratio and mean deviation were stable with decreased best-corrected visual acuity from logMAR 0.72±0.72(20/100) to 1.06±1.13(20/200) (P=0.007). The Kaplan-Meier survival analysis showed median and mean survival of 1205 and 829±91 days, respectively. Complication rate was 47%.
IOP is markedly reduced postoperative day 1 following double glaucoma tube implantation with effects persisting over postoperative year 1 and up to year 5. Complications were higher than that seen in reports of single shunt implantation, which may be explained by patient complexity in this cohort. This technique may prove a promising novel approach for management of uncontrolled IOP in advanced glaucoma.
评估一种新技术——同时植入艾哈迈德(Ahmed)分流管和贝尔维尔德(Baerveldt)分流管,用于改善晚期青光眼且视野缺损威胁中心注视患者的眼压(IOP)控制效果及安全性。
回顾性病例系列研究;纳入2004年10月至2009年10月期间在单一机构接受艾哈迈德分流管和贝尔维尔德分流管同时植入的所有患者。在术前以及术后第1天、第1周、第1个月、第3个月、第6个月、第1年直至第5年每年对记录进行审查。观察指标包括眼压、最佳矫正视力、视野平均偏差、杯盘比、青光眼药物使用数量及并发症。
共纳入59只眼;平均(±标准差)随访时间为26±23个月。原发性开角型青光眼最为常见(n = 37,63%)。46只眼(78%)曾接受过切开手术。术前平均眼压为25.5±9.8毫米汞柱。术后第1天眼压降低了50%(P < 0.001,平均为12.7±7.0毫米汞柱),且在整个随访期间持续降低。在第1年,杯盘比和平均偏差保持稳定,但最佳矫正视力从logMAR 0.72±0.72(20/100)降至1.06±1.13(20/200)(P = 0.007)。Kaplan - Meier生存分析显示,中位生存期和平均生存期分别为1205天和829±91天。并发症发生率为47%。
青光眼双管植入术后第1天眼压显著降低,且效果在术后第1年直至第5年持续存在。并发症发生率高于单分流管植入的报道,这可能与该队列患者病情复杂有关。该技术可能是晚期青光眼眼压控制不佳的一种有前景的新方法。